KEY-T 0.18 BIP.UN-T -0.15 POW-T -0.1 BBD.B-T 1.53 UNH-N -5.61 NTR-T 0.52 TGT-N 1.27
Daily Stock Opinions and Ratings
The ultimate 360° Tracker Your financial life in one place, automatically
Stockchase Opinions

Ian Ainsworth Shire PLC SHPG-Q PAST TOP PICK Feb 04, 2013

(A Top Pick Feb 1/12. Up 2.18%.) Focused on special opportunities in the pharmaceutical world. Got under pressure because there were generics coming in on their key drugs but it turned out the risk wasn’t as threatening as the market had expected. Stock has been rallying lately.

Ian AinsworthIan Ainsworth
Owned
Unlock Rating
$101.400

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

TOP PICK

Shire PLC(SHPG-Q)

Jan 26, 2006
A UK company that does such nervous system pharmaceutical products. The big product is for hyperactive disorder. Adderall, a big seller, does not become generic for three years. Multiple in the high teens. Also has five new products coming out.
Ian AinsworthIan Ainsworth
Owned
Unlock Rating
$47.630

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

Shire PLC(SHPG-Q)

Nov 09, 2006
(A Top Pick Jan 26/05. Up 11%.) Pharma company that’s moving into the biotech space. Have a lot of new products. Does $1.9 billion in revenues and can add another $1.4 billion incremental revenues in the next 4-5 years if the products are approved.
Ian AinsworthIan Ainsworth
No
Unlock Rating
$56.140

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

Shire PLC(SHPG-Q)

Feb 01, 2012
Irish pharmaceutical company and its major franchise is Adderall for attention deficit disorder. The opportunity here is that they can move it into adults. The other part of their business is orphan drugs, drugs that are not targets for large pharmaceuticals.
Ian AinsworthIan Ainsworth
Owned
Unlock Rating
$99.640

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

Shire PLC(SHPG-Q)

May 25, 2016

(Market Call Minute) He likes pharma and the more North American focus. Prefers JNJ-N but is okay with this one.

David BurrowsDavid Burrows
Unknown
Unlock Rating
$191.780

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

Shire PLC(SHPG-Q)

Apr 18, 2017

A pharmaceutical/biotech company. It has an extremely attractive valuation, dirt cheap, trading at under 11X forward earnings. This has a really good stable of rare disease drugs that are very much untouched in the marketplace. The pharmaceutical sector has been absolutely beaten up and is becoming absolutely compelling. Dividend yield of 0.53%. (Analysts’ price target is £6100.)

John StephensonJohn Stephenson
Owned
Unlock Rating
$169.640

Stock price when the opinion was issued

biotechnology pharmaceutical

Your Watchlist

Add stocks to watchlist to monitor them daily and get important alerts.

Latest Buy Signals

CLS-T -3.91$123.45
NVDA-Q 4.58$111.01
PEP-Q -1.93$133.38
IBM-N 3.08$232.41
RMD-N -0.22$235.88

Today's Top Picks

KEY-T 0.18$42.62
BIP.UN… -0.15$39.97
POW-T -0.1$50.8
BBD.B-… 1.53$91.21
UNH-N -5.61$418.64

Popular Articles

Questrade Review: Pros & Cons of Trading with Questrade Canada (2021) Steady Eddys: 3 Stable Stocks Between Safety and Risk: 3 Safe and Gambling Stocks 3 Oversold Stocks to Take Advantage of 5 ETFs for Index Investing

Latest Sell Signals

ARE-T -0.27$15.4
CVX-N -0.34$138.73
XOM-N -0.06$108.57
CNQ-T -0.01$40.68
TD-T -0.03$86.17

Most Recent Experts

Greg Newman

Scotia Wealth Management

Stockchase Insights

5i Research

Jim Cramer - Mad Money

CNBC

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

© Stockchase Inc.